Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gantenerumab - Roche

Drug Profile

Gantenerumab - Roche

Alternative Names: R-1450; RG-1450; RO-4909832

Latest Information Update: 10 Jun 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys
  • Developer Chugai Pharmaceutical; Roche; Washington University School of Medicine
  • Class Antidementias; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 22 May 2020 Phase-III clinical trials in Alzheimer's disease (Treatment-experienced, In children, In adults, In the elderly) in Canada (SC) (NCT04339413) (EudraCT2019-004431-23)
  • 05 May 2020 Roche plans a phase III trial for Alzheimer's disease in Argentina, Chile, Mexico (SC) in August 2020 (NCT04374253)
  • 25 Apr 2020 Efficacy data from the phase III open-label extension SCarlet RoAD and Marguerite RoAD trials in Alzheimer's disease presented at the 72nd Annual Meeting of the American Academy of Neurology (AAN-2020)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top